241 related articles for article (PubMed ID: 15590769)
1. Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors.
Tryoen-Tóth P; Décaillot FM; Filliol D; Befort K; Lazarus LH; Schiller PW; Schmidhammer H; Kieffer BL
J Pharmacol Exp Ther; 2005 Apr; 313(1):410-21. PubMed ID: 15590769
[TBL] [Abstract][Full Text] [Related]
2. Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue.
Labarre M; Butterworth J; St-Onge S; Payza K; Schmidhammer H; Salvadori S; Balboni G; Guerrini R; Bryant SD; Lazarus LH
Eur J Pharmacol; 2000 Oct; 406(1):R1-3. PubMed ID: 11011049
[TBL] [Abstract][Full Text] [Related]
3. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
Szekeres PG; Traynor JR
J Pharmacol Exp Ther; 1997 Dec; 283(3):1276-84. PubMed ID: 9400003
[TBL] [Abstract][Full Text] [Related]
4. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
5. Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception.
Su YF; McNutt RW; Chang KJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):815-23. PubMed ID: 9864259
[TBL] [Abstract][Full Text] [Related]
6. Analysis of inverse agonism at the delta opioid receptor after expression in Rat 1 fibroblasts.
Mullaney I; Carr IC; Milligan G
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):227-34. PubMed ID: 8670111
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human delta-opioid receptor with an inverse agonist.
Piñeyro G; Azzi M; deLéan A; Schiller PW; Bouvier M
Mol Pharmacol; 2005 Jan; 67(1):336-48. PubMed ID: 15496503
[TBL] [Abstract][Full Text] [Related]
8. N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.
Weltrowska G; Nguyen TM; Chung NN; Wilkes BC; Schiller PW
Bioorg Med Chem Lett; 2013 Sep; 23(18):5082-5. PubMed ID: 23932788
[TBL] [Abstract][Full Text] [Related]
9. Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation.
Zaki PA; Keith DE; Thomas JB; Carroll FI; Evans CJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1015-20. PubMed ID: 11504798
[TBL] [Abstract][Full Text] [Related]
10. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.
Schiller PW; Weltrowska G; Berezowska I; Nguyen TM; Wilkes BC; Lemieux C; Chung NN
Biopolymers; 1999; 51(6):411-25. PubMed ID: 10797230
[TBL] [Abstract][Full Text] [Related]
11. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
12. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
13. Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as δ opioid receptor inverse agonists.
Nemoto T; Iihara Y; Hirayama S; Iwai T; Higashi E; Fujii H; Nagase H
Bioorg Med Chem Lett; 2015 Aug; 25(15):2927-30. PubMed ID: 26048798
[TBL] [Abstract][Full Text] [Related]
14. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.
Salvadori S; Attila M; Balboni G; Bianchi C; Bryant SD; Crescenzi O; Guerrini R; Picone D; Tancredi T; Temussi PA
Mol Med; 1995 Sep; 1(6):678-89. PubMed ID: 8529134
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
16. Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.
Emmerson PJ; McKinzie JH; Surface PL; Suter TM; Mitch CH; Statnick MA
Eur J Pharmacol; 2004 Jun; 494(2-3):121-30. PubMed ID: 15212965
[TBL] [Abstract][Full Text] [Related]
17. Agonist Activity of the delta-antagonists TIPP and TIPP-psi in cellular models expressing endogenous or transfected delta-opioid receptors.
Martin NA; Terruso MT; Prather PL
J Pharmacol Exp Ther; 2001 Jul; 298(1):240-8. PubMed ID: 11408548
[TBL] [Abstract][Full Text] [Related]
18. Opioid diketopiperazines: refinement of the delta opioid antagonist pharmacophore.
Bryant SD; Balboni G; Guerrini R; Salvadori S; Tomatis R; Lazarus LH
Biol Chem; 1997 Feb; 378(2):107-14. PubMed ID: 9088539
[TBL] [Abstract][Full Text] [Related]
19. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands.
Calderon SN; Rice KC; Rothman RB; Porreca F; Flippen-Anderson JL; Kayakiri H; Xu H; Becketts K; Smith LE; Bilsky EJ; Davis P; Horvath R
J Med Chem; 1997 Feb; 40(5):695-704. PubMed ID: 9057856
[TBL] [Abstract][Full Text] [Related]
20. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice.
Broom DC; Nitsche JF; Pintar JE; Rice KC; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2002 Nov; 303(2):723-9. PubMed ID: 12388657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
